Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy

Study Identifier
GMA-RES-014-001
CT.gov Identifier
NCT02121847
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Dry Eye
    • Study Drug
  • cyclosporine 0.05% ophthalmic emulsion
  • carboxymethylcellulose-based lubricant eye drops
    • Phase
    Phase 4
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * History of dry eye in both eyes * Willing to use eye drops for dry eye symptoms
    Exclusion Criteria:
    * Anticipate wearing contact lenses during the study * Laser-assisted in situ keratomileusis (LASIK) surgery within the past 12 months * Any ocular and/or lid surgeries within the past 6 months * Cataract surgery in either eye * Current or anticipated use of temporary punctal plugs during the study

    Protocol Summary

    This study will evaluate the safety and efficacy of cyclosporine 0.05% ophthalmic emulsion (Restasis®) in patients with dry eye disease.

    Study Locations

    Location
    Status
    Location
    Andover, Massachusetts, United States
    Status
    Not applicable